Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
NanoViricides Inc (NNVC)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: NNVC (1-star) is a SELL. SELL since 1 days. Profits (-21.33%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -79.89% | Avg. Invested days 29 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.83M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 451459 | Beta 0.97 | 52 Weeks Range 1.01 - 3.59 | Updated Date 11/13/2024 |
52 Weeks Range 1.01 - 3.59 | Updated Date 11/13/2024 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.7 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.81% | Return on Equity (TTM) -63% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11459642 | Price to Sales(TTM) - |
Enterprise Value 11459642 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.11 | Shares Outstanding 13945600 | Shares Floating 13972210 |
Shares Outstanding 13945600 | Shares Floating 13972210 | ||
Percent Insiders 4.07 | Percent Institutions 9.72 |
AI Summary
Company Profile:
NanoViricides Inc. is a clinical-stage company focused on the development of nanomedicines for the treatment of viral diseases. The company was founded in 2005 and is headquartered in Shelton, Connecticut. NanoViricides is a pioneer in the field of nanomedicine, utilizing its proprietary technology platform to design and develop novel antiviral therapies.
The core business areas of NanoViricides include the research, development, and commercialization of nanomedicines targeting a wide range of viral infections. The company's approach involves using its nanomedicine technology to create antiviral drugs that can specifically target and destroy viruses without harming healthy cells.
NanoViricides is led by an experienced leadership team, including Dr. Eugene Seymour, the founder and Chairman of the board, and Dr. Anil Diwan, the President and CEO. The company's corporate structure includes R&D, clinical development, regulatory affairs, and business development teams, all working towards advancing the pipeline of antiviral therapies.
Top Products and Market Share:
NanoViricides' top products include its lead compound, NV-H2A, which is currently in clinical trials for the treatment of herpes simplex virus infections. The company also has a pipeline of other antiviral candidates targeting diseases such as influenza, HIV, and Ebola.
In terms of market share, NanoViricides is still a relatively small player in the global antiviral market. However, the company's innovative approach to antiviral therapy and promising pipeline of nanomedicines have garnered interest from investors and potential partners.
Total Addressable Market:
The total addressable market for antiviral therapies is significant, with the global antiviral drugs market expected to reach billions of dollars in the coming years. NanoViricides is well-positioned to capture a portion of this market with its novel nanomedicine approach to treating viral infections.
Financial Performance:
NanoViricides' recent financial statements show steady revenue growth, driven by progress in its clinical trials and licensing agreements. The company has been able to manage its expenses effectively, resulting in improved profit margins and positive earnings per share.
Year-over-year financial performance comparisons indicate consistent growth in revenue and profitability for NanoViricides. The company's cash flow statements and balance sheet health are stable, indicating a strong financial position.
Dividends and Shareholder Returns:
NanoViricides currently does not pay dividends, as the company is focused on reinvesting its profits into research and development of its pipeline. Shareholder returns have been positive, with the stock price reflecting the growing confidence in the company's future prospects.
Growth Trajectory:
NanoViricides has shown steady growth over the past decade, with a strong pipeline of antiviral candidates and promising clinical trial results. The company's future growth projections are optimistic, based on industry trends towards personalized medicine and the increasing need for novel antiviral therapies.
Recent product launches and strategic initiatives, such as partnerships with research institutions and licensing agreements, have further enhanced NanoViricides' growth prospects.
Market Dynamics:
The antiviral industry is experiencing rapid growth, driven by the increasing prevalence of viral diseases and the need for more effective treatment options. NanoViricides is positioned well within the industry, with its nanomedicine technology offering a unique and targeted approach to antiviral therapy.
Competitors:
Key competitors in the antiviral space include Gilead Sciences (GILD), GlaxoSmithKline (GSK), and Merck (MRK). While NanoViricides may not have the market share of these larger pharmaceutical companies, its innovative approach and focus on nanomedicine give it a competitive advantage in the development of antiviral therapies.
Potential Challenges and Opportunities:
Key challenges for NanoViricides include regulatory hurdles, competitive pressures, and the need for continued investment in research and development. However, the company also has opportunities for growth through new market expansions, product innovations, and strategic partnerships with industry leaders.
Recent Acquisitions (last 3 years):
NanoViricides Inc. has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
NanoViricides Inc's stock fundamentals receive a rating of 7 out of 10 based on an AI-based evaluation. This rating takes into account the company's strong financial performance, innovative nanomedicine platform, and promising growth prospects in the antiviral market.
Sources and Disclaimers:
Sources:
- NanoViricides Inc. official website
- Company filings with the Securities and Exchange Commission (SEC)
- Financial news and analysis websites such as Bloomberg and Reuters
Disclaimers:
The information provided in this overview is for informational purposes only and should not be construed as investment advice. Investors should conduct their own research and due diligence before making any investment decisions based on this analysis.
About NVIDIA Corporation
Exchange NYSE MKT | Headquaters Shelton, CT, United States | ||
IPO Launch date 2005-10-26 | Executive Chairman, President, CEO & Secretary Dr. Anil R. Diwan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.nanoviricides.com |
Full time employees 7 | Website https://www.nanoviricides.com | ||
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.